Utah Medical Products UTMD Effective Income Tax Rate Reconciliation Tax Credits Research

Effective Income Tax Rate Reconciliation Tax Credits Research at other companies

TFX

TeleflexTFX

11.4%+9.7pp

Baxter InternationalBAX

-3.6%—

Avanos MedicalAVNS

-2.3%-3.2pp

Other financials

Income statement

See full

Revenue$8.7M-10.2%

Gross profit$5.3M-4.6%

Operating income$2.6M-18.6%

Net income$2.6M-14.4%

EPS (diluted)$0.82-10.9%

Balance sheet

See full

Cash & equivalents$87.4M+4.9%

Total debt$210.0K—

Total equity$120.4M+2.8%

Total assets$124.4M+1.5%

Cash flow

See full

Operating cash flow$3.1M-30.4%

CapEx$130.0K-29.3%

Free cash flow$3.0M-30.4%

Valuation

See full

Market cap$219.63M+26.4%

Enterprise value$132.44M+42.5%

P/E20.3×+6.4×

P/S5.9×+1.4×

Profitability

See full

Gross margin57.9%-0.4pp

Operating margin28.8%-3.9pp

Net margin28.9%-4.1pp

FCF margin34.7%0.0pp

Returns & leverage

See full

Return on equity9.1%-1.4pp

Debt / equity0×—

Current ratio28.6×+6.3×

Where this comes from

Reported directly by Utah Medical Products in its filing.

Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch.

The official record: Utah Medical Products’s 10-K, filed March 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about Utah Medical Products's effective income tax rate reconciliation tax credits research.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Utah Medical Products's effective income tax rate reconciliation tax credits research?: Utah Medical Products (UTMD) reported effective income tax rate reconciliation tax credits research of 0.1% in Q4 2025.
What does effective income tax rate reconciliation tax credits research mean?: This metric measures the percentage point reduction in the effective tax rate attributable to research and development tax credits. It serves as a key indicator of the tax-saving benefits realized from the company's R&D activities.